Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Crexavibart (BMS-986413; C-144-LS), an IgG1 λ2 antibody, specifically targets the receptor-binding domain of the SARS-CoV-2 spike (S) glycoprotein [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Crexavibart (BMS-986413; C-144-LS), an IgG1 λ2 antibody, specifically targets the receptor-binding domain of the SARS-CoV-2 spike (S) glycoprotein [1]. |
Synonyms | BMS-986413, C-144-LS |
Molecular Weight | N/A |
CAS No. | 2599039-61-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Crexavibart 2599039-61-7 Microbiology/Virology SARS-CoV BMS-986413 C-144-LS inhibitor inhibit